WO2005002590A1 - 骨量増加誘導剤 - Google Patents
骨量増加誘導剤 Download PDFInfo
- Publication number
- WO2005002590A1 WO2005002590A1 PCT/JP2004/009604 JP2004009604W WO2005002590A1 WO 2005002590 A1 WO2005002590 A1 WO 2005002590A1 JP 2004009604 W JP2004009604 W JP 2004009604W WO 2005002590 A1 WO2005002590 A1 WO 2005002590A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- bone
- compound
- bisphosphonate
- bone mass
- pyridazine
- Prior art date
Links
- 210000000988 bone and bone Anatomy 0.000 title claims abstract description 105
- 230000001939 inductive effect Effects 0.000 title claims abstract description 9
- 150000001875 compounds Chemical class 0.000 claims abstract description 144
- 230000001737 promoting effect Effects 0.000 claims abstract description 71
- 229940122361 Bisphosphonate Drugs 0.000 claims abstract description 57
- 150000004663 bisphosphonates Chemical class 0.000 claims abstract description 56
- 230000004072 osteoblast differentiation Effects 0.000 claims abstract description 55
- 239000000203 mixture Substances 0.000 claims abstract description 50
- 208000001132 Osteoporosis Diseases 0.000 claims abstract description 29
- 239000003814 drug Substances 0.000 claims abstract description 28
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 25
- 230000037118 bone strength Effects 0.000 claims abstract description 22
- 208000029725 Metabolic bone disease Diseases 0.000 claims abstract description 17
- 230000007423 decrease Effects 0.000 claims abstract description 10
- -1 nitrogen-containing heterocyclic compound Chemical class 0.000 claims description 78
- 125000001424 substituent group Chemical group 0.000 claims description 54
- 238000002360 preparation method Methods 0.000 claims description 40
- 150000003839 salts Chemical class 0.000 claims description 31
- 238000000034 method Methods 0.000 claims description 29
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 24
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims description 24
- 230000001965 increasing effect Effects 0.000 claims description 23
- 210000000963 osteoblast Anatomy 0.000 claims description 23
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 23
- 239000000411 inducer Substances 0.000 claims description 20
- 229920006395 saturated elastomer Polymers 0.000 claims description 20
- 125000000623 heterocyclic group Chemical group 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 125000000217 alkyl group Chemical group 0.000 claims description 15
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 14
- 125000002950 monocyclic group Chemical group 0.000 claims description 14
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 14
- 125000005842 heteroatom Chemical group 0.000 claims description 13
- 125000001072 heteroaryl group Chemical group 0.000 claims description 12
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 claims description 11
- 229940062527 alendronate Drugs 0.000 claims description 11
- 208000030136 Marchiafava-Bignami Disease Diseases 0.000 claims description 10
- 229910052736 halogen Inorganic materials 0.000 claims description 10
- 150000002367 halogens Chemical class 0.000 claims description 10
- 230000002708 enhancing effect Effects 0.000 claims description 9
- 229940124597 therapeutic agent Drugs 0.000 claims description 9
- 125000003118 aryl group Chemical group 0.000 claims description 8
- 230000008416 bone turnover Effects 0.000 claims description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
- VMMKGHQPQIEGSQ-UHFFFAOYSA-N minodronic acid Chemical compound C1=CC=CN2C(CC(O)(P(O)(O)=O)P(O)(O)=O)=CN=C21 VMMKGHQPQIEGSQ-UHFFFAOYSA-N 0.000 claims description 7
- 229950011129 minodronic acid Drugs 0.000 claims description 7
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 6
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 6
- 230000003449 preventive effect Effects 0.000 claims description 6
- 229940089617 risedronate Drugs 0.000 claims description 6
- 125000002947 alkylene group Chemical group 0.000 claims description 4
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- 125000002883 imidazolyl group Chemical group 0.000 claims description 4
- 125000003003 spiro group Chemical group 0.000 claims description 4
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 3
- 230000004069 differentiation Effects 0.000 claims description 3
- 239000003623 enhancer Substances 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 125000006501 nitrophenyl group Chemical group 0.000 claims description 3
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 claims description 3
- 229940046231 pamidronate Drugs 0.000 claims description 3
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 3
- 125000003944 tolyl group Chemical group 0.000 claims description 3
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 claims description 2
- 125000003107 substituted aryl group Chemical group 0.000 claims description 2
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 claims description 2
- 229960004276 zoledronic acid Drugs 0.000 claims description 2
- YKALSAFWGKGKLO-UHFFFAOYSA-N 3-(3-bromophenyl)-6-piperidin-1-yl-[1,2,4]triazolo[4,3-b]pyridazine Chemical compound BrC1=CC=CC(C=2N3N=C(C=CC3=NN=2)N2CCCCC2)=C1 YKALSAFWGKGKLO-UHFFFAOYSA-N 0.000 claims 1
- KTKPVYXFTOUSNG-UHFFFAOYSA-N 6-(azepan-1-yl)-3-(6-methoxypyridin-2-yl)-[1,2,4]triazolo[4,3-b]pyridazine Chemical compound COC1=CC=CC(C=2N3N=C(C=CC3=NN=2)N2CCCCCC2)=N1 KTKPVYXFTOUSNG-UHFFFAOYSA-N 0.000 claims 1
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 claims 1
- 101710176384 Peptide 1 Proteins 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 125000000068 chlorophenyl group Chemical group 0.000 claims 1
- 150000001923 cyclic compounds Chemical class 0.000 claims 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical group C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 claims 1
- GPKUICFDWYEPTK-UHFFFAOYSA-N methoxycyclohexatriene Chemical group COC1=CC=C=C[CH]1 GPKUICFDWYEPTK-UHFFFAOYSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 39
- 208000006386 Bone Resorption Diseases 0.000 abstract description 20
- 230000024279 bone resorption Effects 0.000 abstract description 20
- 229940079593 drug Drugs 0.000 abstract description 13
- 208000010392 Bone Fractures Diseases 0.000 abstract description 10
- 230000002401 inhibitory effect Effects 0.000 abstract description 9
- 230000004097 bone metabolism Effects 0.000 abstract description 7
- 208000008035 Back Pain Diseases 0.000 abstract description 3
- 208000002193 Pain Diseases 0.000 abstract description 3
- 230000036407 pain Effects 0.000 abstract description 3
- 239000000463 material Substances 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 51
- 238000004519 manufacturing process Methods 0.000 description 44
- 230000002829 reductive effect Effects 0.000 description 40
- 239000000243 solution Substances 0.000 description 36
- 238000006243 chemical reaction Methods 0.000 description 34
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 29
- 238000012360 testing method Methods 0.000 description 27
- 239000013078 crystal Substances 0.000 description 26
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
- 230000001054 cortical effect Effects 0.000 description 20
- 230000011164 ossification Effects 0.000 description 20
- 230000037182 bone density Effects 0.000 description 19
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 18
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 18
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 18
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 18
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 17
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 16
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 239000002253 acid Substances 0.000 description 12
- 229940126062 Compound A Drugs 0.000 description 11
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- 239000007864 aqueous solution Substances 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 206010017076 Fracture Diseases 0.000 description 10
- 108090000445 Parathyroid hormone Proteins 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 229950006971 incadronic acid Drugs 0.000 description 10
- 210000002700 urine Anatomy 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- ZAHDXEIQWWLQQL-IHRRRGAJSA-N Deoxypyridinoline Chemical compound OC(=O)[C@@H](N)CCCC[N+]1=CC(O)=C(C[C@H](N)C([O-])=O)C(CC[C@H](N)C(O)=O)=C1 ZAHDXEIQWWLQQL-IHRRRGAJSA-N 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 9
- ZZFKAZHZSSJSSE-UHFFFAOYSA-L disodium;[(cycloheptylamino)-[hydroxy(oxido)phosphoryl]methyl]-hydroxyphosphinate;hydrate Chemical compound O.[Na+].[Na+].OP(O)(=O)C(P([O-])([O-])=O)NC1CCCCCC1 ZZFKAZHZSSJSSE-UHFFFAOYSA-L 0.000 description 9
- 239000003480 eluent Substances 0.000 description 9
- 238000001914 filtration Methods 0.000 description 9
- 230000002485 urinary effect Effects 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 8
- 238000001816 cooling Methods 0.000 description 8
- 102100036893 Parathyroid hormone Human genes 0.000 description 7
- 206010039984 Senile osteoporosis Diseases 0.000 description 7
- 238000010992 reflux Methods 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000005755 formation reaction Methods 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 238000010898 silica gel chromatography Methods 0.000 description 6
- 210000002303 tibia Anatomy 0.000 description 6
- FXYQRYGWWZKUFV-UHFFFAOYSA-N (6-chloropyridazin-3-yl)hydrazine Chemical compound NNC1=CC=C(Cl)N=N1 FXYQRYGWWZKUFV-UHFFFAOYSA-N 0.000 description 5
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 125000005843 halogen group Chemical group 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 210000000689 upper leg Anatomy 0.000 description 5
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 238000012937 correction Methods 0.000 description 4
- 230000007547 defect Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 4
- 230000001747 exhibiting effect Effects 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 239000003701 inert diluent Substances 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 229920000609 methyl cellulose Polymers 0.000 description 4
- 239000001923 methylcellulose Substances 0.000 description 4
- 238000013001 point bending Methods 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 4
- 125000004076 pyridyl group Chemical group 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 125000005943 1,2,3,6-tetrahydropyridyl group Chemical group 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 102000003982 Parathyroid hormone Human genes 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 235000003704 aspartic acid Nutrition 0.000 description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 210000003275 diaphysis Anatomy 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 229940011871 estrogen Drugs 0.000 description 3
- 239000000262 estrogen Substances 0.000 description 3
- 210000002436 femur neck Anatomy 0.000 description 3
- 238000005227 gel permeation chromatography Methods 0.000 description 3
- 239000004220 glutamic acid Substances 0.000 description 3
- 235000013922 glutamic acid Nutrition 0.000 description 3
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Substances NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 238000000691 measurement method Methods 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 210000002997 osteoclast Anatomy 0.000 description 3
- 208000005368 osteomalacia Diseases 0.000 description 3
- 210000001672 ovary Anatomy 0.000 description 3
- 239000000199 parathyroid hormone Substances 0.000 description 3
- 229960001319 parathyroid hormone Drugs 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 125000005936 piperidyl group Chemical group 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- LETVJWLLIMJADE-UHFFFAOYSA-N pyridazin-3-amine Chemical compound NC1=CC=CN=N1 LETVJWLLIMJADE-UHFFFAOYSA-N 0.000 description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 239000008247 solid mixture Substances 0.000 description 3
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 3
- KZKRRZFCAYOXQE-UHFFFAOYSA-N 1$l^{2}-azinane Chemical group C1CC[N]CC1 KZKRRZFCAYOXQE-UHFFFAOYSA-N 0.000 description 2
- CBHTTYDJRXOHHL-UHFFFAOYSA-N 2h-triazolo[4,5-c]pyridazine Chemical class N1=NC=CC2=C1N=NN2 CBHTTYDJRXOHHL-UHFFFAOYSA-N 0.000 description 2
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- MUMVJRMQOGAXBB-UHFFFAOYSA-N 6-(azepan-1-yl)-3-(6-bromopyridin-2-yl)-[1,2,4]triazolo[4,3-b]pyridazine Chemical compound BrC1=CC=CC(C=2N3N=C(C=CC3=NN=2)N2CCCCCC2)=N1 MUMVJRMQOGAXBB-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102000055006 Calcitonin Human genes 0.000 description 2
- 108060001064 Calcitonin Proteins 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 201000002980 Hyperparathyroidism Diseases 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- 208000008930 Low Back Pain Diseases 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 229920001007 Nylon 4 Polymers 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 102000008108 Osteoprotegerin Human genes 0.000 description 2
- 108010035042 Osteoprotegerin Proteins 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- DKJJVAGXPKPDRL-UHFFFAOYSA-N Tiludronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)SC1=CC=C(Cl)C=C1 DKJJVAGXPKPDRL-UHFFFAOYSA-N 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 150000008065 acid anhydrides Chemical class 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 238000005452 bending Methods 0.000 description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 229940088623 biologically active substance Drugs 0.000 description 2
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 2
- 229960004015 calcitonin Drugs 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 150000004777 chromones Chemical class 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 238000006482 condensation reaction Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 208000020089 femoral neck fracture Diseases 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 239000007758 minimum essential medium Substances 0.000 description 2
- PUUSSSIBPPTKTP-UHFFFAOYSA-N neridronic acid Chemical compound NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O PUUSSSIBPPTKTP-UHFFFAOYSA-N 0.000 description 2
- 229950010733 neridronic acid Drugs 0.000 description 2
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- XXUPLYBCNPLTIW-UHFFFAOYSA-N octadec-7-ynoic acid Chemical compound CCCCCCCCCCC#CCCCCCC(O)=O XXUPLYBCNPLTIW-UHFFFAOYSA-N 0.000 description 2
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000009806 oophorectomy Methods 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 229940083251 peripheral vasodilators purine derivative Drugs 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 125000000561 purinyl group Chemical class N1=C(N=C2N=CNC2=C1)* 0.000 description 2
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 125000005493 quinolyl group Chemical group 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 125000006413 ring segment Chemical group 0.000 description 2
- 210000003625 skull Anatomy 0.000 description 2
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 150000003577 thiophenes Chemical class 0.000 description 2
- 229940019375 tiludronate Drugs 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 210000004746 tooth root Anatomy 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 235000005282 vitamin D3 Nutrition 0.000 description 2
- 239000011647 vitamin D3 Substances 0.000 description 2
- 229940021056 vitamin d3 Drugs 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- NTCBUXIQMLORSI-GIDUJCDVSA-N (e)-1-[4-(4-bromophenyl)phenyl]-3-phenylprop-2-en-1-one Chemical compound C1=CC(Br)=CC=C1C1=CC=C(C(=O)\C=C\C=2C=CC=CC=2)C=C1 NTCBUXIQMLORSI-GIDUJCDVSA-N 0.000 description 1
- WJUKOGPNGRUXMG-UHFFFAOYSA-N 1,2-dibromo-1,1,2,2-tetrachloroethane Chemical compound ClC(Cl)(Br)C(Cl)(Cl)Br WJUKOGPNGRUXMG-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- NPOVTGVGOBJZPY-UHFFFAOYSA-N 1-isocyanato-3-methoxybenzene Chemical compound COC1=CC=CC(N=C=O)=C1 NPOVTGVGOBJZPY-UHFFFAOYSA-N 0.000 description 1
- BLRHMMGNCXNXJL-UHFFFAOYSA-N 1-methylindole Chemical compound C1=CC=C2N(C)C=CC2=C1 BLRHMMGNCXNXJL-UHFFFAOYSA-N 0.000 description 1
- FFLPIVZNYJKKDM-UHFFFAOYSA-N 1-phenylmethoxycarbonylpiperidine-3-carboxylic acid Chemical compound C1C(C(=O)O)CCCN1C(=O)OCC1=CC=CC=C1 FFLPIVZNYJKKDM-UHFFFAOYSA-N 0.000 description 1
- VFYFMNCKPJDAPV-UHFFFAOYSA-N 2,2'-(5-oxo-1,3-dioxolan-4,4-diyl)diessigs Chemical compound C1N(C2)CN3CN1CN2C3.OC(=O)CC1(CC(O)=O)OCOC1=O VFYFMNCKPJDAPV-UHFFFAOYSA-N 0.000 description 1
- ALXBXKJAVGIBDQ-UHFFFAOYSA-N 2-(quinolin-2-ylamino)benzoic acid Chemical class OC(=O)C1=CC=CC=C1NC1=CC=C(C=CC=C2)C2=N1 ALXBXKJAVGIBDQ-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- NDOPHXWIAZIXPR-UHFFFAOYSA-N 2-bromobenzaldehyde Chemical compound BrC1=CC=CC=C1C=O NDOPHXWIAZIXPR-UHFFFAOYSA-N 0.000 description 1
- 125000006276 2-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C(*)C([H])=C1[H] 0.000 description 1
- LNWZYGXSVPIBKJ-UHFFFAOYSA-N 3-(3-methoxyphenyl)-6-piperidin-1-yl-[1,2,4]triazolo[4,3-b]pyridazine Chemical compound COC1=CC=CC(C=2N3N=C(C=CC3=NN=2)N2CCCCC2)=C1 LNWZYGXSVPIBKJ-UHFFFAOYSA-N 0.000 description 1
- NUPJINXSWBVYOJ-UHFFFAOYSA-N 3-(6-piperidin-1-yl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)aniline Chemical compound NC1=CC=CC(C=2N3N=C(C=CC3=NN=2)N2CCCCC2)=C1 NUPJINXSWBVYOJ-UHFFFAOYSA-N 0.000 description 1
- NEGFNJRAUMCZMY-UHFFFAOYSA-N 3-(dimethylamino)benzoic acid Chemical compound CN(C)C1=CC=CC(C(O)=O)=C1 NEGFNJRAUMCZMY-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
- RPESZQVUWMFBEO-UHFFFAOYSA-N 3-cyanobenzoyl chloride Chemical compound ClC(=O)C1=CC=CC(C#N)=C1 RPESZQVUWMFBEO-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- WXNZTHHGJRFXKQ-UHFFFAOYSA-N 4-chlorophenol Chemical compound OC1=CC=C(Cl)C=C1 WXNZTHHGJRFXKQ-UHFFFAOYSA-N 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- 125000000590 4-methylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- LUFOEALABTXOLN-UHFFFAOYSA-N 6-(azocan-1-yl)-3-(6-methoxypyridin-2-yl)-[1,2,4]triazolo[4,3-b]pyridazine Chemical compound COC1=CC=CC(C=2N3N=C(C=CC3=NN=2)N2CCCCCCC2)=N1 LUFOEALABTXOLN-UHFFFAOYSA-N 0.000 description 1
- NFEVIIPDTWKORJ-UHFFFAOYSA-N 6-[6-(azepan-1-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]-1h-pyridin-2-one Chemical compound OC1=CC=CC(C=2N3N=C(C=CC3=NN=2)N2CCCCCC2)=N1 NFEVIIPDTWKORJ-UHFFFAOYSA-N 0.000 description 1
- ZLKMOIHCHCMSFW-UHFFFAOYSA-N 6-chloropyridine-2-carboxylic acid Chemical compound OC(=O)C1=CC=CC(Cl)=N1 ZLKMOIHCHCMSFW-UHFFFAOYSA-N 0.000 description 1
- RCACEWGZYBNDRT-UHFFFAOYSA-N 6-hydrazinyl-n-methyl-n-phenylpyridazin-3-amine Chemical compound C=1C=C(NN)N=NC=1N(C)C1=CC=CC=C1 RCACEWGZYBNDRT-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 208000018083 Bone metabolism disease Diseases 0.000 description 1
- 229940078581 Bone resorption inhibitor Drugs 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- TWIAKCQWGZENKT-UHFFFAOYSA-N COC1=CC=CC(=N1)C1=NN=C2N1N=CC=C2 Chemical compound COC1=CC=CC(=N1)C1=NN=C2N1N=CC=C2 TWIAKCQWGZENKT-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- GXGJIOMUZAGVEH-UHFFFAOYSA-N Chamazulene Chemical group CCC1=CC=C(C)C2=CC=C(C)C2=C1 GXGJIOMUZAGVEH-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 101710167839 Morphogenetic protein Proteins 0.000 description 1
- NWMZLDKGPIWERA-UHFFFAOYSA-N N'-(6-chloropyridazin-3-yl)-3-cyanobenzohydrazide Chemical compound N1=NC(Cl)=CC=C1NNC(=O)C1=CC=CC(C#N)=C1 NWMZLDKGPIWERA-UHFFFAOYSA-N 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical class ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- FZERHIULMFGESH-UHFFFAOYSA-N N-phenylacetamide Chemical compound CC(=O)NC1=CC=CC=C1 FZERHIULMFGESH-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- LCYXYLLJXMAEMT-SAXRGWBVSA-N Pyridinoline Chemical compound OC(=O)[C@@H](N)CCC1=C[N+](C[C@H](O)CC[C@H](N)C([O-])=O)=CC(O)=C1C[C@H](N)C(O)=O LCYXYLLJXMAEMT-SAXRGWBVSA-N 0.000 description 1
- 238000012951 Remeasurement Methods 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 108010049264 Teriparatide Proteins 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000005910 alkyl carbonate group Chemical group 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- ALBMDAUNCYEVLB-UHFFFAOYSA-N azepan-1-ylmethanol Chemical compound OCN1CCCCCC1 ALBMDAUNCYEVLB-UHFFFAOYSA-N 0.000 description 1
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- QXNDZONIWRINJR-UHFFFAOYSA-N azocane Chemical compound C1CCCNCCC1 QXNDZONIWRINJR-UHFFFAOYSA-N 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
- 239000012965 benzophenone Substances 0.000 description 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 239000002617 bone density conservation agent Substances 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 230000010072 bone remodeling Effects 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 230000003913 calcium metabolism Effects 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- ZCDOYSPFYFSLEW-UHFFFAOYSA-N chromate(2-) Chemical group [O-][Cr]([O-])(=O)=O ZCDOYSPFYFSLEW-UHFFFAOYSA-N 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 description 1
- 229960002286 clodronic acid Drugs 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- PSLIMVZEAPALCD-UHFFFAOYSA-N ethanol;ethoxyethane Chemical compound CCO.CCOCC PSLIMVZEAPALCD-UHFFFAOYSA-N 0.000 description 1
- 238000006266 etherification reaction Methods 0.000 description 1
- 125000005677 ethinylene group Chemical group [*:2]C#C[*:1] 0.000 description 1
- MVEAAGBEUOMFRX-UHFFFAOYSA-N ethyl acetate;hydrochloride Chemical compound Cl.CCOC(C)=O MVEAAGBEUOMFRX-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 229940009626 etidronate Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- REHUGJYJIZPQAV-UHFFFAOYSA-N formaldehyde;methanol Chemical compound OC.O=C REHUGJYJIZPQAV-UHFFFAOYSA-N 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 229940015872 ibandronate Drugs 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000005945 imidazopyridyl group Chemical group 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000001055 magnesium Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- NBTOZLQBSIZIKS-UHFFFAOYSA-N methoxide Chemical compound [O-]C NBTOZLQBSIZIKS-UHFFFAOYSA-N 0.000 description 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical compound [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000006772 olefination reaction Methods 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 208000025061 parathyroid hyperplasia Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 230000003239 periodontal effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 235000007686 potassium Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 150000003166 prostaglandin E2 derivatives Chemical class 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000005412 pyrazyl group Chemical group 0.000 description 1
- RUUOPSRRIKJHNH-UHFFFAOYSA-N pyridazine-3-carboxylic acid Chemical compound OC(=O)C1=CC=CN=N1 RUUOPSRRIKJHNH-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 108091006084 receptor activators Proteins 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 238000006277 sulfonation reaction Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- OGBMKVWORPGQRR-UMXFMPSGSA-N teriparatide Chemical compound C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CNC=N1 OGBMKVWORPGQRR-UMXFMPSGSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention provides a bone metabolic disease comprising a combination of a non-living non-peptidic osteoblast differentiation promoting compound, particularly a nitrogen-containing heterocyclic compound represented by the following general formula (I) or a salt thereof, and a bisphosphonate.
- a non-living non-peptidic osteoblast differentiation promoting compound particularly a nitrogen-containing heterocyclic compound represented by the following general formula (I) or a salt thereof, and a bisphosphonate.
- pharmaceutical compositions or combinations useful for the prevention and treatment of bone diseases such as Background art
- osteoporosis In normal bone metabolism, bone resorption by osteoclasts and bone formation by osteoblasts are in equilibrium, and homeostasis is maintained. If this balance between bone resorption and bone formation is disrupted, it is thought to be a metabolic bone disease.
- the diseases include osteoporosis, fibrous osteomyelitis (hyperparathyroidism), osteomalacia, and Pageet's disease, which affects systemic bone metabolic parameters.
- Osteoporosis that causes pain such as low back pain and bone fractures includes primary osteoporosis, which is often found in postmenopausal women, such as accelerated bone turnover (type I) and senile decreased bone turnover (type II), and steroids. Secondary (secondary) osteoporosis induced by administration or the like is known.
- parathyroid hormone ⁇ : parathyroid hormone
- PTHrP PTH- related protein
- TNF TNF
- M-CSF active vitamin D3 (la, 25 (0H) 2 D 3)
- prostaglandin prostaglandin
- RA KL receptor activator of NF-fcB ligand
- OPG osteoprotegerin
- PTH bone growth
- BMP bone growth
- bisphosphonate is a compound having a structure similar to that of pyrophosphate, a calcification-inhibiting substance.It inhibits the function of osteoclasts and has the effect of inhibiting bone resorption, so it is used in metabolic bone diseases such as osteoporosis. It is a drug used for treatment. For example, it has been reported that alendronate or risedrone, a typical bisphosphonate, reduced the frequency of femoral neck fractures in a large-scale clinical study of postmenopausal female osteoporosis patients (Non-patented). Reference 1: New England Journal of Medicine. 333 (22), p. 1437-1443, (1995) and Non-Patent Reference 2: New England Journal of Medicine.
- Non-Patent Document 2 the effect was not significant in elderly patients aged 80 and over (Non-Patent Document 2), suggesting that a sufficient effect cannot be expected in senile osteoporosis. .
- Non-Patent Document 1 WO 96/074157
- Non-Patent Document 3 R. Neer et al., Bone, 32 (5), S69, (2003).
- PGE2 Prostaglandin E2
- alendronate a bioactive substance clinically used as a vasodilator and labor-inducing agent
- Non-peptidic compounds having alkaline phosphatase (ALP) -inducing activity and having osteoblast differentiation promoting activity have been reported.
- purine derivatives Non-Patent Document 5: J.
- Patent Document 12 JP-A-9-188622
- These conjugates exhibiting an osteoblast differentiation promoting action exhibit an osteogenesis promoting action and are disclosed to be useful for the treatment of metabolic bone diseases and fractures. It is still unknown.
- Patent publications disclosing these compounds also state that these osteoblast differentiation promoting compounds can be used in combination with other bone mass increase inducers or bone resorption inhibitors. Include bisphosphonates (for example, Patent Documents 2, 3, 5, and 7). However, there is no specific example in which the osteoblast differentiation promoting compound is used in combination with the bisphosphonate, or the effect of the combination is not disclosed at all.
- Patent Document 14 German Patent No. 2,444,322
- Patent Document 15 Japanese Patent Application Laid-Open No. 50-58092.
- Patent Documents 16, 17 and 18 Dot published patents 2, 261, 693, 2, 254, 873 and 2, And an antimicrobial compound in which R is 5-nitro-2-furyl or 5-nitro-2-thenyl (Patent Documents 19, 20, and 21: Doi Patent Publication 2, 161, Nos. 586, 2, 161, 587 and 2, 113, 438).
- the present inventors have conducted intensive studies for the purpose of developing a therapeutic agent having a bone formation promoting action by promoting the function of osteoblasts.
- the novel nitrogen-containing heterocyclic compound represented by the following general formula (I) is excellent.
- Osteoblast differentiation promoting activity and can be a prophylactic or therapeutic agent for metabolic bone disease as an osteogenesis promoter, similar to known non-living non-peptidic osteoblast differentiation promoting compounds.
- filed a patent application earlier WO 03/074525 pamphlet.
- the nitrogen-containing heterocyclic compound which is a favorable compound for promoting osteoblast differentiation, has been obtained.
- the bone mass increase inducer is an agent for preventing or treating bone turnover (type II) osteoporosis
- Bone mass increase inducer consisting of two preparations, a first preparation containing a non-biologically derived non-peptide osteoblast differentiation promoting compound and a second preparation containing a bisphosphonate-containing preparation Wherein the first and second formulations are administered simultaneously or separately,
- the first preparation is a preparation containing a nitrogen-containing heterocyclic compound represented by the following general formula (I) or a salt thereof:
- a method for preventing or treating a metabolic bone disease accompanied by a decrease in bone mass and / or bone strength of a patient comprising an effective amount of a non-living non-peptidic osteoblast differentiation compound, Administering a quantity of a bisphosphonate, simultaneously or separately,
- Ra and Rb the same or different, H; CO- lower alkyl; S0 2 - lower alkyl; optionally substituted cycloalkyl; which may have a substituent Ariru; or a substituent A cycloalkyl which may have a substituent, an aryl which may have a substituent, a 4- to 8-membered monocyclic saturated or partially unsaturated heterocyclic ring which may have a substituent, CO— lower alkyl, S0 2 - lower alkyl, OR ⁇ SR NRiR 2 halogen, N0 2, CN, 1 ⁇ 3 amino lower alkyl which may have a substituent selected from the group consisting ⁇ Pi COOR 1; however At least one of R a and R b represents a group other than H,
- Ra and Rb are combined with an adjacent N atom to form a 4- to 8-membered saturated or partially unsaturated heterocyclic ring containing 1 to 2 N atoms as a hetero atom, and the hetero ring is It may be condensed with a benzene ring or a cycloalkyl ring, may have a bridge, or may form a spiro ring.
- R aryl which may have a substituent, heteroaryl which may have a substituent, cycloalkyl which may have a substituent, cycloalkenyl which may have a substituent or substitution
- a 4- to 8-membered monocyclic saturated or partially unsaturated heterocyclic group which may have a group i3 ⁇ 4,
- R ⁇ R 6 same or different, H or lower alkyl
- Ra and Rb are united with adjacent N atoms to form piperidino, E is a single bond, and R is piperidino, unsubstituted phenol, P- (trifluoromethyl ) Compounds which are phenyl, phenyl or nitrophenyl;
- R a and R b are taken together with an adjacent N atom to form 4-methyl-1-piperazinyl, E is a single bond, and R is unsubstituted phenyl, p-methylphenyl, a compound which is m_methylphenyl, p-methoxyphenyl, m-chlorophenyl, p-chlorophenol or m-trophenyl,
- FIG. 1 is a graph showing the results of femoral bone strength (three-point bending test) in Test 1 of Example 2. Note that ***, ** and * indicate that the results of the Student's st-test for the control group 1 were P-0.005, P-0.01 and P-0.05, respectively.
- FIG. 2 is a graph showing the results of femoral cortical bone density (pQCT) in Test 1 of Example 2.
- pQCT femoral cortical bone density
- FIG. 3 is a graph showing the results of femoral cortical bone width (pQCT) in Test 1 of Example 2. Note that ** and * indicate that the results of the 'Student' test for the control group 1 are P ⁇ 0.05, P ⁇ 0.01 and P ⁇ 0.05, respectively.
- FIG. 4 is a graph showing the urinary deoxypyridinoline value (urine volume correction) in Test 1 of Example 2.
- FIG. 5 is a graph showing the results of tibial cortical bone width (pQCT) in Test 2 of Example 2. * Indicates that the result of the Student's st-test for the control group 1 is P ⁇ 0.05.
- FIG. 6 is a graph showing the results of the tibial cortical bone density (pQCT) in Test 2 of Example 2. '
- FIG. 7 is a graph showing the urinary deoxy ⁇ / pyridinoline level (urine volume correction) in Test 2 of Example 2. Note that ***, **, and * indicate that the results of the Student's st-test for the control group 1 were P ⁇ 0.05, P ⁇ 0.01, and P ⁇ 0.05, respectively.
- a non-living non-peptidic osteoblast differentiation promoting compound refers to a compound that promotes differentiation induction into osteoblasts or osteoblasts themselves to promote osteoblast function, A low-molecular-weight organic compound that clearly shows the ALP activity promoting action of osteoblasts, and does not include existing biologically active substances derived from living organisms or analogs thereof, and does not include peptide compounds.
- ALP is elevated from the early stage of osteoblast function expression (Journal 'ob' Cellular Physiology, 143, 420 (1990)) and is involved in osteoblast-induced bone formation. (Cell Engineering, Vol. 13, No. 12, 1062 (1994), and J. Clin. Invest., 89, 1974 (1992)) indicate that an increase in ALP activity is an indicator of osteogenesis promotion by promoting osteoblast differentiation induction. It is evaluated as
- the “osteoblast differentiation promoting compound” of the present invention is obtained by a method similar to the method of Lowry et al. Using osteoblasts (Journal of Biological Chemistry, 207, 19 (1954)). The compound was confirmed to have ALP promoting activity in the ALP activity measurement test used. ALP activity 'for cells with partial I human ability to one osteoblasts or osteoblast even without least
- cells that can be used for the ALP activity measurement test include mouse skull-derived osteoblast cell line MC3T3-El, rat neonatal skull-derived cell line ROB-C26, C8a, Cll, C20, C23, rat osteosarcoma cells Strain R0S17 / 2.8, human osteoblast NH0st, mouse undifferentiated mesenchymal cell line C3H10Tl / 2, human mesenchymal stem cell hMSC, and other various (mouse, rat, human, etc.) osteoblasts and bone Cells, undifferentiated mesenchymal stem cells, bone marrow cells, etc., and the ALP promoting activity is confirmed in these cells.
- Non-living non-peptidic osteoblast differentiation promoting compounds have been reported, for example, benzocepin derivatives (Patent Documents 2 to 4), chromone derivatives (Patent Document 5), and thiophene derivatives (Patent References 6 to 11), purine derivatives (Non-patent Reference 5), N-quinolylanthranilic acid derivatives (Patent References 12) and the like are suitable as the non-peptide osteoblast differentiation promoting compound of the present invention.
- These compounds can be easily obtained by the methods described in the patent literature or non-patent literature.
- the ALP promoting activity of these compounds is as described in the patent document or non-patent document.
- Example 1 a newly synthesized compound, a commercially available product, various compounds registered in a chemical file, or a compound group obtained by a combinatorial chemistry technique is subjected to an ALP activity measurement test described in Example 1 below.
- a compound exhibiting ALP promoting activity that can be used as the non-peptide osteoblast fraction promoting compound of the present invention can be found.
- the compound thus found can be chemically modified to obtain a more active non-peptide osteoblast differentiation promoting compound.
- the nitrogen-containing heterocyclic compound represented by the above general formula '(I) (hereinafter abbreviated as compound (I)) or a salt thereof, which has been discovered by the present inventors, has a good osteoblast component promoting action. Therefore, it is particularly preferable as the non-peptide osteoblast differentiation promoting compound of the present invention.
- lower means a straight or branched carbon chain having 1 to 6 carbon atoms, unless otherwise specified.
- lower alkyl a methyl, ethyl and propyl group are particularly preferred.
- a 1 k “lower, lower alkyl” is abbreviated as “A 1 k”.
- Ariru is preferably a C 6- i 4 monocyclic to tricyclic Ariru group. More preferred Is a phenyl and naphthyl group, more preferably a phenyl group. Also Hue
- - C 5 8 cycloalkyl ring is condensed to a group, for example, may form a indanyl or tetrahydronaphthyl group.
- Cycloalkyl is preferably a C 3 _ 1 4 cycloalkyl group which may have a bridge. More preferably, they are C3- I0 cycloalkyl groups, and still more preferably, they are cyclopentyl, cyclohexyl and cycloheptyl groups. “Cycloalkenyl” is a group having one or two double bonds in the above “cycloalkyl” ring.
- 4- to 8-membered monocyclic saturated or partially unsaturated heterocyclic ring is a 4- to 8-membered monocyclic saturated heterocyclic ring containing 1 to 4 heteroatoms selected from N, S and O. And may have a cross-link, and may partially have an unsaturated bond.
- Preferred are tetrahydrovillal, tetrahydrofuranyl, pyrrolidinyl, piperidyl, 1,2,3,6-tetrahydropyridyl, homopiridinyl, piperazinole, homopiperazinyl, quinutalidinyl and morpholininole groups.
- Heteroaryl includes a 5- to 6-membered monocyclic heteroaryl group containing 1 to 4 heteroatoms selected from N, S and O, and a benzene ring or a 5- to 6-membered monocyclic heteroaryl.
- the 5- or 6-membered monocyclic heteroaryl includes frill, cher, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxoxazolyl, oxdiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyrimidyl, pyrimidyl , Pyrazyl and triazinyl groups are preferred, and examples of the bicyclic or tricyclic heteroaryl include benzofuranyl, benzocell, benzothiadiazolyl, benzothiazolyl, benzoxazolyl, benzoxaziazolyl, benzimidazolyl, indolyl, and isoindolyl.
- Indazolyl quinolyl, isoquinolyl, cinnolinyl, quinazolinyl, quinoxalinyl, benzodioxolyl, pyrazinopyridyl, triazolopyridyl, naphthy Jiniru ⁇ Pi Imidazopirijiru group Shi-liked,.
- Examples of the partially saturated heteroaryl include a 1,2,3,4-tetrahydroquinolyl group and the like.
- the heteroaryl is more preferably a pyridyl, pyrimidinyl, furyl, phenyl, thiazolyl, quinolyl, benzofuranyl, benzothenyl, indolyl, imidazopyridyl and naphthyridinyl group, and particularly preferably a pyridyl group.
- ⁇ Cycloalkyl optionally having a substituent '', ⁇ cycloalkenyl optionally having a substituent '', ⁇ optionally having a substituent, 4- to 8-membered
- the substituent in the ⁇ ring-saturated or partially unsaturated heterocyclic ring '' is preferably the same or different 1 to 5 substituents selected from the following group B, more preferably selected from group B1 And particularly preferably halogen, OA 1 k and SA 1 k.
- R 1 and R 2 are as described above; “Group D” is Alk, halogen, nodogeno Alk, NR ⁇ RNO 2 , CN, OR 1 and SR 1 ; “Group G” is halogen , NRiR 2 CN, COOR 1 , OR ⁇ SR ⁇ A 4- to 8-membered monocyclic saturated or partially unsaturated heterocyclic ring which may have 1 to 4 substituents selected from the group Aryl which may have 1 to 4 substituents selected from group D, and heteroaryl which may have 1 to 4 substituents selected from group D; , Br, F and C 1; and “halogeno Alk” each represent a lower alkyl (particularly preferably CF 3 ) substituted with one or more halogen atoms. The same applies hereinafter.
- Group B1 A 1 k, halogen, halogeno A 1 k, NR'R 2, N0 2, CN, OR 1, .- O- halogeno A lk, SR COOR 1, CONRiR 2 S0 2 A lk, 4 to 8-membered Monocyclic saturated or partially unsaturated heterocyclic ring, phenyl and phenoxy group.
- a "4- to 8-membered saturated or partially unsaturated heterocycle containing 1 to 2 heteroatoms containing 1 to 2 N atoms" formed by Ra and Rb together with an adjacent N atom is a ring atom. And the remaining ring atoms are C-atoms, 4 to 8 membered monocyclic saturated or partially unsaturated heterocyclic groups.
- the heterocyclic ring may form a benzene ring or a C 5 _ 8 cycloalkyl ring and condensed ring may have a bridge, but it may also form a spiro ring.
- it is a 4- to 8-membered monocyclic saturated or partially unsaturated heterocyclic ring which may have a cross-linking, and among them, lipidinyl, piperidyl, homopiperidinyl, perhydroazo shell, 1,2, 3, 6-tetrahydropyridyl, 3-azabisik mouth [3.2.1] octyl, 8-azabisik mouth [3.2.1] octyl, 3-azabizik mouth [3.2.2] Noril and 3-azabizik mouth [3.3 .1] is a nor group. A pyridyl group is particularly preferred.
- the hetero ring may have a substituent, and the substituent is preferably 1 to 5 substituents selected from the aforementioned Group B. More preferably, (A 1 k which may have a substituent selected from COOR 1 OR 1 and phenyl), halogen, NR iR 2 , CN, OR—O— (from COOR OR 1 and phenyl A 1 k) with selected substituents, 1 to 5 substituents selected from phenyl, and particularly preferably 1 to 2 substituents selected from A 1k, rho, logen, .OR 1 and COOR 1 .
- (1) -NR a Rb force may be condensed with a benzene ring or a cycloalkyl ring, may have a cross-link or may form a spiro ring, and has 1 to 5 members selected from the group B
- the aryl is optionally substituted with 1 to 5 substituents, or is selected from the group B.
- E is a single bond, 1-3 alkylene, bi- or ethynylene;
- R is group B1 A compound which is an aryl having 1 to 5 substituents selected from or a heteroaryl having 1 to 5 substituents selected from the group B1.
- One NR a R b force may have one N atom as a ring hetero atom and may have a bridge, and may have one or two selected from A 1 k, halogen, OR 1 and COOR 1
- Particularly preferred compounds are the nitrogen-containing heterocyclic compounds listed below or salts thereof.
- 6-azocan-1-yl-3- (6-methoxypyridine-2-yl) -1,2,4-triazolo [4,3-b] pyridazine, 6-azepane-1-yl- 3- (6-Bromopyridine-2-yl) -1,2,4-triazolo [4,3-b] pyridazine, 3- (3-methoxyphenyl) -6- (piperidine-1-yl ) -1,2,4-Triazolo [4,3-b] pyridazine, 3- (3-bromophenyl) -6- (piperidine-1-yl) -1,2,4-triazo mouth [4,3- b] pyridazine, 6-azepan-1-yl-3--(6-methoxypyridine-2-yl) -1,2,4-tri [4,3-b] pyridazine, 6- (4
- the compound (I) may form an acid addition salt or a salt with a base depending on the type of the substituent.
- the kagul salt is a pharmaceutically acceptable salt, preferably an inorganic acid such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, phosphoric acid, formic acid, acetic acid, and propion.
- Acid oxalic acid
- Acid addition salts with organic acids such as malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, methanesulfonic acid, ethanesulfonic acid, aspartic acid, glutamic acid, sodium, potassium, magnesium
- organic bases containing metals such as calcium, aluminum and the like, salts with organic bases such as methylamine, ethynoleamine, ethanolamine, lysine and ordithine, and ammonium salts.
- the compound (I) of the present invention also includes various hydrates, solvates and polymorphs of salts thereof.
- the compound (I) of the present invention has a good ALP-promoting activity as shown in Example 1 described below, and itself has a bone formation-promoting effect by promoting osteoblast differentiation induction.
- the “bisphosphonate” is a bisphosphonic acid having a bone resorption inhibiting effect or a pharmaceutically acceptable salt or ester thereof, preferably etidronate, alendronate; Japanese Patent Publication No. Hei 2-13645, Japanese Patent Publication No. 6-62651, US Patent No. 4705651), risedronate (risedronate; Japanese Patent No. 2702419, Japanese Patent No. 2568999, European Patent No. 186405), Midronate (Patent No. 5-8717, U.S. Pat. No. 4,327,039), Incadronate (Indonesia 7-629), Clodronate, Minodronate, Minodronate; -99457 gazette)
- alendronate More preferred are alendronate, risedronate, pamidronate, incadronate, minodronate, iband mouth salt and zoledroneate, particularly preferably alendronate, risedronate, incadronate, minodronate and zoledroneate.
- compositions of bisphosphonic acids include inorganic bases including metals such as sodium, potassium, magnesium, calcium, and aluminum, and organic bases such as methylamine, ethylamine, ethanolamine, lysine, and onolenitine. Salts.
- the ester is preferably a lower alkyl ester such as methinoleestenole and ethyl ester.
- the term “bone mass increase inducer” refers to a drug that increases bone mass and / or bone strength, and is preferably a drug that increases both bone mass and bone strength. Therefore, the “bone mass increase inducer” of the present invention includes osteoporosis, fibrous ostitis (parathyroid hyperplasia), osteomalacia, pageet disease, etc., accompanied by a decrease in bone mass and Z or bone strength.
- Prophylactic or therapeutic agent for metabolic bone disease bone tissue repair agent for bone tissue damage such as fracture, refracture, bone defect, osteoarthritis, multiple myeloma, bone metastasis of cancer; and dentistry It includes a periodontal disease therapeutic agent, a periodontal tissue defect repair agent, an artificial tooth root stabilizing agent, a ridge formation promoter and the like in the region.
- the ⁇ bone mass increase inducer '' of the present invention is preferably a preventive or therapeutic agent for metabolic bone diseases such as osteoporosis, and particularly preferably a bone turnover-reduced type ( ⁇ type) having a reduced bone formation ability. It is an agent for preventing or treating osteoporosis, especially senile osteoporosis.
- the “combination” means an independent preparation of each component, which can be used for combination therapy. They may be packaged in combination (for example, in the form of a kit or the like) or may be sold separately for combined administration.
- “simultaneously” means that the first and second preparations are administered together, and “separately” means that the first and second preparations are the same or different by the same administration route. Alternatively, it means that they are separately administered at different administration frequencies or administration intervals.
- they are administered simultaneously or separately under administration conditions such as formulation, administration route, administration frequency and the like suitable for each preparation.
- the kit contains a first preparation containing a non-peptidic osteoblast differentiation compound and a second preparation containing bisphosphonate.
- Examples include packages that may contain additional formulations or labeling components.
- the term "agent for enhancing the effect of increasing bone mass” refers to an agent which, when another agent has an effect of inducing bone loss as a result, cooperates with the effect to further increase the amount of bone.
- Bisphosphonate refers to a drug that enhances the effect of an osteoblast differentiation promoting compound on bone mass because the effect of increasing the bone mass of the osteoblast differentiation promoting compound is enhanced by the combined use of bisphosphonate.
- the osteoblast differentiation promoting compound it means an agent that enhances the action of bisphosphonate to increase bone mass, since the effect of increasing the bone mass of bisphosphonate is enhanced by the combined use of the osteoblast differentiation promoting compound.
- the pharmaceutical composition containing the non-biologically derived non-peptide osteoblast differentiation compound of the present invention and a bisphosphonate, and the first preparation or the second preparation constituting the combination of the present invention can be prepared by those skilled in the art. It can be formulated using known techniques. That is, it can be prepared by a commonly used method using pharmaceutical carriers, excipients, and other additives usually used in the preparation of pharmaceuticals.
- pharmaceutical carriers for oral administration, tablets, pills, capsules, granules, powders, liquids, inhalants, etc., or injections such as intravenous injections, intramuscular injections, suppository transdermal solutions, ointments, and transdermal patches Any form of parenteral administration with an agent or the like may be used.
- the solid composition for oral administration tablets, powders, granules and the like are used.
- one or more active '1 1 raw material least also one inert diluent such as lactose, mannitol, glucose, hydroxypropyl Le cellulose, microcrystalline cellulose, starch , Polybutylpyrrolidone, mixed with magnesium metasilicate aluminate.
- the composition may contain, in a conventional manner, an additive other than an inert diluent, for example, a lubricant such as magnesium stearate, a disintegrating agent such as calcium dalicholate, a stabilizer, glutamic acid or aspartic acid.
- tablets or pills may be coated with a sugar coating such as sucrose, gelatin, hydroxypropynolesenorelose, hydroxypropylmethylcellulose phthalate or a film of a gastric or enteric substance.
- a sugar coating such as sucrose, gelatin, hydroxypropynolesenorelose, hydroxypropylmethylcellulose phthalate or a film of a gastric or enteric substance.
- Liquid compositions for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, elixirs and the like, commonly used inert diluents, For example, purified water and ethanol are included.
- the composition may contain, in addition to the inert diluent, adjuvants such as wetting agents and suspending agents, sweetening agents, flavoring agents, fragrances, and preservatives.
- Injections for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions.
- Aqueous solutions and suspensions include, for example, distilled water for injection and physiological saline.
- water-insoluble solutions and suspensions include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, alcohols such as ethanol, and Polysorbate 80 (trade name).
- Such compositions may also include preservatives, wetting agents, emulsifying agents, dispersing agents, stabilizers, solubilizing agents (eg, glutamic acid, aspartic acid).
- Such adjuvants may be included.
- These are sterilized by, for example, filtration through a filter for retaining bacteria, blending of a fungicide, or irradiation. They can also be used in the manufacture of a sterile solid composition which is dissolved in sterile water or a sterile solvent for injection before use.
- WO 94/05297 pamphlet WO 99/04773 pamphlet, U.S. Patent No. 5358941, WO 99/18972 pamphlet, WO 97/44017 pamphlet, WO
- Various technologies relating to bisphosphonate-containing preparations are disclosed in the pamphlet of 2000/21541, the pamphlet of WO 2001/82903, the pamphlet of WO 2001/76577, etc. Thus, a desired bisphosphonate-containing preparation can be produced.
- the non-biologically derived non-peptide osteoblast differentiation promoting compound in the pharmaceutical composition or combination of the present invention is orally or parenterally administered at a dose exhibiting osteoblast differentiation promoting activity.
- a non-peptidic osteoblast differentiation promoting compound derived from a non-living body known in the literature a suitable dose and administration form described in the literature can be adopted.
- the compound (I) of the present invention when used, its daily dose is about 0.001 to 100 mg / kg, preferably 0.01 to 60 mg / kg per body weight when administered orally. This is administered once or in 2 to 4 divided doses.
- the dose is about 0.0001 to 20 mg / kg per body weight, preferably about 0.001 to 5 mg / kg, and is administered once a day or divided into a plurality of doses.
- it may be administered for several days to several months, for example, once a week, twice a week, twice a month, once a month and the like.
- the non-living non-peptidic osteoblast differentiation-promoting compound of the present invention may be locally administered as a local injection or depot to a desired site of bone formation.
- the bisphosphonate in the pharmaceutical composition or the combination of the present invention is orally or parenterally administered at a dose exhibiting the activity of inhibiting bone resorption.
- the daily dose of the bisphosphonate is determined according to the activity of the bisphosphonate used. Dosage suitable for clinical use ⁇ For bisphosphonates for which the frequency of administration is known, the relevant clinical dose. It is preferred to administer at the frequency of administration. Alternatively, a smaller amount may be administered in consideration of the synergistic effect with the osteoblast differentiation promoting compound.
- 0.001 to 30 mg per day preferably 0.01 to 10 mg / day. mg is appropriate once a day, or for several days to several months, for example, once a week, Administer twice a week, twice a month, once a month, etc.
- approximately 0.0001 from lmg / k g per body weight preferably suitably 0. 5 mg / kg to about 0.001, which once a day, Moshiku a few days to several months
- the dose should be administered once a week, once every two weeks, once a month, once every three months, once every six months, once a year, etc.
- both components are prepared and manufactured so as to include the amounts corresponding to the above dosages. .
- the compound (I) and its salt can be produced by applying various known synthetic methods by utilizing the characteristics based on the basic skeleton or the type of the substituent. At that time, depending on the type of the functional group, if it is effective for production technology to replace the functional group with an appropriate protecting group at the raw material or intermediate stage, that is, a group that can be easily converted to the functional group, There is. Thereafter, the desired compound can be obtained by removing the protecting group as necessary.
- a functional group include a hydroxyl group and a carboxyl group.
- Examples of such a protecting group include Green and Wuts, “Protective Groups in Organic Synthesis”, 2nd edition. These may be used as appropriate according to the reaction conditions! The representative production methods are described below.
- L represents a conventional leaving group such as a halogen atom or an organic sulfonate.
- Compound (I) is obtained by conventional alkylation, for example, an amine derivative (III) and a halogen atom or an organic compound.
- Compound (II) having a common leaving group such as sulfonate can be combined with ⁇ dimethylformamide (DMF), tonolene, tetrahydrofuran in the presence or absence of potassium carbonate, triethylamine, sodium hydride, etc.
- the reaction can be carried out in an inert solvent such as (THF), aceto-tolyl or the like, or without a solvent under cooling to reflux.
- the compound obtained by the first production method is further subjected to a conventional substituent modification reaction, for example, a reduction reaction of a nitro group to an amino group, amidation, sulfonamidation, alkylation, esterification, esterification.
- a conventional substituent modification reaction for example, a reduction reaction of a nitro group to an amino group, amidation, sulfonamidation, alkylation, esterification, esterification.
- the compound of the present invention having a desired substituent can be obtained by subjecting the compound to hydrolysis, etherification of a hydroxyl group, sulfonation of a thioether, halogenation, or olefination. These reactions are for example, can be easily performed according ORGANIC FUNCTIONAL GROUP PREPARATIONS Second Edition (Sandler , Ka ro Author) to the method described in the like.
- the starting compound (II) can be produced by subjecting a hydrazine compound (IV) and a carboxylic acid compound (V) to a dehydration condensation reaction to form a hydrazide compound (VI) and then cyclizing the same.
- the dehydration-condensation reaction in the first step can be carried out by a conventional method, for example, with a free carboxylic acid and a condensing agent such as: 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide (WSCD).
- a condensing agent such as: 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide (WSCD).
- carboxylic acid such as 1,1'-carbonyldiimidazole, or a reactive derivative of carboxylic acid (eg, acid halide such as acid chloride, acid bromide; acid azide; methanol Active esters that can be prepared using ethanol, ethanol, benzyl alcohol, optionally substituted phenol, hydroxysuccinimide, etc .; symmetric acid anhydrides; alkyl carbonates, P-toluenesulfonate, etc. (Mixed acid anhydride, etc.).
- carboxylic acid such as 1,1'-carbonyldiimidazole
- a reactive derivative of carboxylic acid eg, acid halide such as acid chloride, acid bromide; acid azide; methanol Active esters that can be prepared using ethanol, ethanol, benzyl alcohol, optionally substituted phenol, hydroxysuccinimide, etc .
- symmetric acid anhydrides alkyl carbonates, P-toluenes
- the reaction is carried out in an organic solvent inert to the reaction, for example, pyridine, THF, methylene chloride, DMF, acetonitrile and the like, using an equimolar amount or one of them in excess.
- organic solvent inert for example, pyridine, THF, methylene chloride, DMF, acetonitrile and the like.
- the reaction is appropriately selected depending on the type of the reactive derivative. Depending on the type of reactive derivative, it may be advantageous to add a base such as 4-dimethylaminopyridine to promote the reaction.
- the cyclization reaction in the second step is performed in the presence or absence of an acid such as acetic acid, toluenesulfonic acid, or an acid.
- the reaction can be carried out in the presence of a solvent such as xylene or ethylene glycol, or without a solvent. This reaction can be carried out at room temperature or under reflux.
- Starting compound (IX) is obtained by condensing compound (IV) and isocyanate compound (VII) in a reaction-inert solvent such as acetonitrile to obtain compound (VIII), and then reacting in the presence of a base such as triethylamine. It can be produced by adding 1,2-jibu-mo-1,1,2,2-tetrachloroethane and triphenylenophosphine and cycling. The reaction can be suitably carried out at room temperature or under reflux with heating according to a conventional method.
- the reaction product obtained by each of the above-mentioned production methods is isolated and purified as a free compound, a salt thereof, a ⁇ -hydrate, or various solvates.
- the salt can be produced by subjecting the salt to a usual salt formation reaction. Isolation and purification are carried out by applying ordinary chemical operations such as extraction, concentration, distillation, crystallization, filtration, recrystallization, and various types of chromatography.
- Various isomers can be isolated by a conventional method using the physicochemical difference between the isomers.
- the optical isomers can be separated by a general optical resolution method, for example, fractional crystallization or chromatography. Further, the optical isomer can also be synthesized from a suitable optically active starting compound.
- Phosphorus cells After washing with acid buffered saline, the substrate was added and incubated at 37 ° C for 10-15 minutes. The reaction by adding Natoriumu hydroxide 0.
- the bone strength of the diaphysis was measured by a three-point bending test (TK-252C, Muromachi Kikai).
- the femur was allowed to stand on a support having a distance between the fulcrums of 20 ram, a bending load was applied to the central portion of the diaphysis at a rate of 10 marauds / min, and a load-displacement curve until fracture was recorded.
- the maximum value of the load-strain curve is the maximum rupture strength (fai lure load), and the slope of the maximum slope section before the yield point of the curve is the bending stiffness. It was.
- Lysylpyridinoline (hereinafter referred to as "deoxypyridinoline") as a bone metabolic marker was measured by SRL's Medisearch by the HPLC method (Uebelhart, D et al., Bone Miner. Vol. 8, page 87 (1990)). did. To eliminate the effects of urine volume, the resulting urinary deoxypyridinoline level was corrected by dividing by urine creatine concentration or multiplying by 24-hour urine volume
- the compound of Production Example 93 (6- (4-fluoropiperidin-1-yl)-, which is a representative compound of compound (I), 3- (6-methoxypyridine-2-yl) -1, 2,4-triazolo [4,3-b] pyridazine: hereinafter abbreviated as compound A) is converted to incadronate (bisfonal (registered trademark)) as a bisphosphonate. , Yamanouchi Pharmaceutical).
- the group to which the compound A or incadronate alone or the parathyroid hormone hPTH (l-34) was administered was set as a comparative group.
- the 0VX group without drug administration and the sham operation group (sham) were used as control groups.
- Compound A was orally administered twice daily as a 30 mg / 5 ml / kg 0.5% methylcellulose suspension, and minderonate was orally administered once daily as an lmg / 2.5 ml / kg aqueous solution .
- hPTH (1-34) was subcutaneously administered once a day as a ⁇ g / lml / kg saline solution.
- the control group was orally administered 0.5% methylcellulose twice a day.
- Compound A of the present invention 30 mg orally twice a day, 6 days a week
- Figure 1 shows the results of femoral bone strength (three-point bending test)
- Figure 2 shows the results of femoral cortical bone density (pQCT)
- Figure 3 shows the results of femoral cortical bone width (PQCT).
- Figure 4 shows the urinary deoxypyridinoline value (urine volume correction).
- Compound A was orally administered twice daily as a 30 mg / 5 ml / kg 0.5% methylcellulose suspension, and alendronate was orally administered once daily as a 3 mg / 2.5 ml / kg aqueous solution.
- the control group was orally administered 0.5% methylcellulose twice daily and water once daily.
- Fig. 5 shows the tibial cortical bone width (pQCT)
- Fig. 6 shows the tibial cortical bone density (pQCT)
- Fig. 7 shows the urinary deoxypyridinoline value (urine volume correction).
- the administration group of the present invention significantly increased the cortical bone width of the tibia and increased the bone mass more favorably than the comparative groups 1 and 2 after administration for only 4 weeks.
- the remarkable effects on the femoral or tibia cortical bone density, width, and strength in the combination administration group of the present invention far exceeded the additive effects of each of the single administration groups (Comparative Group 1 and Comparative Group 2).
- This is due to the synergistic effect of non-living non-peptidic osteoblast differentiation compound on bone metabolism and the effect of bisphosphonate on bone resorption. It was inferred that the whole body was well controlled and that bone mass and strength increased synergistically or more than additively.
- the current treatment using bisphosphonate or PTH is not enough to prevent clinically severe femoral neck (cortical bone) fractures.
- the present invention can significantly increase the strength of cortical bone. The combination is considered to be very useful clinically. .
- Compound A which has a good osteoblast fractionation promoting effect in vitro, increased urinary deoxypyridinoline, which is an indicator of bone resorption, when administered alone (FIGS. 4 and 7). This indicates that the bone resorption activity was also increased. That is, since the osteoblast differentiation promoting compound enhances bone formation and also enhances bone resorption and enhances bone turnover as a whole, the effect of enhancing bone mass and / or Z or bone strength was not sufficient. It was speculated. On the other hand, in the combination administration group of the present invention, the decrease in urinary deoxypyridinolysin value (see FIGS. 4 and 7) is presumed to suppress the enhancement of bone resorption, and bisphosphonate contained osteoblasts.
- Reference Example 1 A mixture of (6-co-mouth pyridazine-3-yl) hydrazine, 4-di-benzo-benzoic acid, WSCD hydrochloride and THF was stirred at room temperature for 2 hours. Water was added to the reaction solution, and the deposited precipitate was collected by filtration, washed with water and dimethyl ether, and N,-(6-chloropyridazine-3-yl) -4-2-1, benzophenone was added. You got Drazide.
- Reference Example 3 A mixture of (6-chloropyridazine-3-yl) hydrazine, 3-dimethylaminobenzoic acid, WSCD hydrochloride and THF was stirred at room temperature for 2 hours. Water was added to the reaction solution, and the deposited precipitate was collected by filtration, washed with water and diisopropyl ether, and N ′-(6-cu-pyridazin-3-yl) -3-dimethylaminobenzohydrazide Got. Ethylene glycol was added thereto, and the mixture was stirred at 160 ° C for 4 hours.
- Production Example 1 A mixture of 3_ (6-kuguchiguchi-1,2,4-triazolo [4,3-b] pyridazin-3-yl) benzo-tolyl (450 mg) and piperidine (5 ml) was prepared. The mixture was stirred under heating and reflux for 2 hours. The reaction solution was concentrated under reduced pressure, and the obtained residue was extracted with chloroform. The extract was washed with a saturated aqueous solution of ammonium chloride and saturated saline, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure.
- Acetic acid 80 ml was added to the obtained residue, and the mixture was stirred at 110 ° C for 2 days, and then the solvent was distilled off under reduced pressure.
- the obtained crude crystals were washed with ethanol and stirred in piperidine (10 ml) under heating and reflux for 3 hours.
- Ethanol 40 ml
- 10% palladium on carbon 150 mg were added to the obtained colorless solid, and the mixture was stirred at room temperature under a hydrogen atmosphere for 6 hours, and then the catalyst was removed by filtration.
- Production Example 14 A 1 M aqueous solution of sodium hydroxide (30 ml) was added to a THF solution (200 ml) of ethyl 2-aminothiazole-4-carboxylate (4.56 g), and the mixture was stirred at room temperature for 3 hours. To the reaction mixture was added 1 M hydrochloric acid (30 ml), and the mixture was concentrated. The resulting residue was dissolved in DMF (50 ml), and 6-chloropyridazine-3-ylhydrazine (3.83 g) and WSCD hydrochloride ( 6.09 g) was added, and the mixture was stirred at room temperature.
- the compound of Preparation Example 113 was prepared in the same manner as in Preparation Example 10, the compounds of Preparation Examples 114 to 116, and the compounds of Preparation Examples 117 and 118 were prepared in the same manner as in Preparation Example 11.
- the compound of Example 119 and the compounds of Production Examples 120 to 121 were obtained in the same manner as in Production Example 17, respectively.
- Tables 3 to 4 below show the structural formulas and physicochemical properties of the reference example compounds
- Tables 5 to 13 show the structural formulas and physical properties of the production example compounds.
- the compounds shown in Table 14 were prepared using the appropriate starting compounds in substantially the same manner as in the above-mentioned Preparation Examples or Preparation Methods, or by applying slight modifications obvious to those skilled in the art. This is an example of compound (I) which is easily produced by application.
- Alendronate is mixed with lactose 35.Og and corn starch 5g, kneaded with polyvinylpyrrolidone K30 (1.0g) size liquid, granulated through 20 mesh sieve, and granulated at 50 ° C. After drying for 2 hours, pass through a 24 mesh sieve.
- Compound A is similarly granulated using the remaining lactose, corn starch and polypyrrolidone K30 paste solution. Both particles are mixed with talc and magnesium stearate, and filled into hardened capsules 200 mg each to produce capsules.
- Example 5 Kit
- Kits with PTP packaging have industrial applicability
- the non-living non-peptidic osteoblast differentiation promoting compound of the present invention has a bone resorption inhibiting effect.
- Pharmaceutical compositions or combinations containing bisphosphonates are useful as bone mass increase inducers to control bone metabolism to increase bone mass and Z or bone strength.
- an agent for preventing or treating a metabolic bone disease such as osteoporosis, fibrous ostitis (hyperparathyroidism), osteomalacia, Pageet's disease, etc., accompanied by a decrease in bone mass and Z or bone strength
- Bone tissue repair agent for bone tissue damage such as bone fracture, refracture, bone defect, osteoarthritis, multiple myeloma, cancer bone metastasis, etc .
- It is useful as a repair agent for defects, a stabilizing agent for artificial dental roots, and a promoter for ridge formation.
- it is expected as a prophylactic or therapeutic agent for metabolic bone diseases such as osteoporosis, and especially as a preventive or therapeutic agent for senile osteoporosis with reduced bone formation ability.
- the agent for enhancing the bone mass increasing effect of bisphosphonate containing the non-living non-peptidic osteoblast differentiation promoting compound of the present invention as an active ingredient is a low bone metabolic turnover state due to long-term administration of bisphosphonate. It is also useful as a preventive agent for weakening and excessive mineralization of the fine bone structure due to accumulation of old bone, and delay of the fracture healing (repair) process.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Surgery (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04747073A EP1640010A1 (en) | 2003-07-01 | 2004-06-30 | Agent inducing increase in bone mass |
JP2005511387A JPWO2005002590A1 (ja) | 2003-07-01 | 2004-06-30 | 骨量増加誘導剤 |
US10/563,107 US20060173009A1 (en) | 2003-01-07 | 2004-06-30 | Agent inducing increase in bone mass |
CA002529558A CA2529558A1 (en) | 2003-07-01 | 2004-06-30 | Agent inducing increase in bone mass |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-189837 | 2003-01-07 | ||
JP2003189837 | 2003-07-01 | ||
JP2003420912 | 2003-12-18 | ||
JP2003-420912 | 2003-12-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005002590A1 true WO2005002590A1 (ja) | 2005-01-13 |
Family
ID=33566746
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/009604 WO2005002590A1 (ja) | 2003-01-07 | 2004-06-30 | 骨量増加誘導剤 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20060173009A1 (ja) |
EP (1) | EP1640010A1 (ja) |
JP (1) | JPWO2005002590A1 (ja) |
CA (1) | CA2529558A1 (ja) |
WO (1) | WO2005002590A1 (ja) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008543764A (ja) * | 2005-06-09 | 2008-12-04 | ブリストル−マイヤーズ スクイブ カンパニー | 11β−ヒドロキシステロイドデヒドロゲナーゼI型阻害剤としてのイミダゾおよびトリアゾロピリジン類 |
WO2009017222A1 (ja) * | 2007-08-02 | 2009-02-05 | Teijin Pharma Limited | 骨代謝異常に起因する疾患の予防剤又は治療剤 |
US8030305B2 (en) | 2005-12-21 | 2011-10-04 | Janssen Pharmaceutica N.V. | Triazolopyridazines as kinase modulators |
JP2011529876A (ja) * | 2008-08-01 | 2011-12-15 | ドン ファ ファーマシューティカル カンパニー リミテッド | ベンズアミジン誘導体またはその塩、およびビスフォスフォネートを含む骨粗鬆症の予防または治療用薬学組成物 |
JP2011529875A (ja) * | 2008-08-01 | 2011-12-15 | ドン ファ ファーマシューティカル カンパニー リミテッド | ベンズアミジン誘導体またはその塩、およびアレンドロン酸またはその塩を含む骨粗鬆症の予防または治療用薬学的組成物 |
WO2012174487A3 (en) * | 2011-06-17 | 2013-04-25 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
US8796261B2 (en) | 2010-12-02 | 2014-08-05 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
US8816082B2 (en) | 2010-05-28 | 2014-08-26 | The Royal Institution For The Advancement Of Learning/Mcgill University | Heterocyclyl-pyridinyl-based biphosphonic acid, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof |
US9249161B2 (en) | 2010-12-02 | 2016-02-02 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
US9290526B2 (en) | 2010-05-28 | 2016-03-22 | The Royal Institution For The Advancement Of Learning/Mcgill University | Heterocyclyl-pyridinyl-based biphosphonic acid, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof |
US9422292B2 (en) | 2011-05-04 | 2016-08-23 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
US9493483B2 (en) | 2012-06-06 | 2016-11-15 | Constellation Pharmaceuticals, Inc. | Benzo [C] isoxazoloazepine bromodomain inhibitors and uses thereof |
US9624244B2 (en) | 2012-06-06 | 2017-04-18 | Constellation Pharmaceuticals, Inc. | Benzo [B] isoxazoloazepine bromodomain inhibitors and uses thereof |
US9969747B2 (en) | 2014-06-20 | 2018-05-15 | Constellation Pharmaceuticals, Inc. | Crystalline forms of 2-((4S)-6-(4-chlorophenyl)-1-methyl-4H-benzo[C]isoxazolo[4,5-e]azepin-4-yl)acetamide |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8217177B2 (en) | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
PE20121506A1 (es) | 2006-07-14 | 2012-11-26 | Amgen Inc | Compuestos triazolopiridinas como inhibidores de c-met |
US8198448B2 (en) | 2006-07-14 | 2012-06-12 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
TW200817410A (en) | 2006-08-07 | 2008-04-16 | Incyte Corp | Triazolotriazines as kinase inhibitors |
SI3034075T1 (sl) | 2006-11-22 | 2018-12-31 | Incyte Holdings Corporation | Imidazotriazini in imidazopirimidini kot inhibitorji kinaze |
WO2009005675A1 (en) * | 2007-06-28 | 2009-01-08 | Abbott Laboratories | Novel triazolopyridazines |
KR101706784B1 (ko) | 2008-05-21 | 2017-02-14 | 인사이트 홀딩스 코포레이션 | 2-플루오로-N-메틸-4-[7-(퀴놀린-6-일-메틸)-이미다조[1,2-b][1,2,4]트리아진-2-일]벤즈아미드의 염 및 이의 제조 방법 |
US9169279B2 (en) | 2009-07-31 | 2015-10-27 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
US20160016982A1 (en) | 2009-07-31 | 2016-01-21 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
LT2459176T (lt) | 2009-07-31 | 2017-12-11 | Grünenthal GmbH | Kristalizacijos būdas ir bioprieinamumas |
CN102812027B (zh) | 2010-02-03 | 2015-01-07 | 因西特公司 | 作为C-MET抑制剂的咪唑并[1,2-b][1,2,4]三嗪 |
US9340565B2 (en) | 2010-11-24 | 2016-05-17 | Thar Pharmaceuticals, Inc. | Crystalline forms |
JO3394B1 (ar) * | 2014-07-04 | 2019-10-20 | Osteo Pharma B V | تركيبات ومنتجات للاستعمال في علاج كسور وعيوب العظام |
US10195218B2 (en) | 2016-05-31 | 2019-02-05 | Grunenthal Gmbh | Crystallization method and bioavailability |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001507338A (ja) * | 1996-11-25 | 2001-06-05 | メルク エンド カンパニー インコーポレーテッド | 疾患を治療するために同時投与されるアンドロゲン物質とビスホスホン酸物質 |
JP2001163862A (ja) * | 1999-09-27 | 2001-06-19 | Sankyo Co Ltd | テトラヒドロピリダジン誘導体 |
JP2002541095A (ja) * | 1999-04-06 | 2002-12-03 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | アリールアルカノイルピリダジンの使用 |
JP2004002318A (ja) * | 2002-03-01 | 2004-01-08 | Yamanouchi Pharmaceut Co Ltd | 含窒素複素環化合物 |
JP2004504351A (ja) * | 2000-07-19 | 2004-02-12 | イーライ・リリー・アンド・カンパニー | 骨量増加の増強方法 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ236618A (en) * | 1990-01-03 | 1997-06-24 | Ciba Geigy Ag | Treating and preventing osteoporosis using insulin-like growth factor i (igf i) in conjunction with a bone antiresorptive active compound |
TW403757B (en) * | 1994-12-28 | 2000-09-01 | Takeda Chemical Industries Ltd | Optically active benzothiepin derivative, its preparation and use |
US5910492A (en) * | 1995-06-05 | 1999-06-08 | Takeda Chemical Industries, Ltd. | Osteogenic promoting pharmaceutical composition |
AU4135397A (en) * | 1996-09-06 | 1998-03-26 | Takeda Chemical Industries Ltd. | Condensed 4,5,6,7-tetrahydrobenzo{c}thiophenes as enhancer for cell differentiation induction factor action |
US6376477B2 (en) * | 1996-11-25 | 2002-04-23 | Merck & Co., Inc. | Combination of an agent that binds to the androgen receptor and a bisphosphonic acid in the prevention and/or treatment of diseases involving calcium or phosphate metabolism |
US6355672B1 (en) * | 1998-08-07 | 2002-03-12 | Takeda Chemical Industries, Ltd. | Benzothiepin derivatives, process for the preparation of the same and uses thereof |
WO2001016127A1 (fr) * | 1999-09-01 | 2001-03-08 | Takeda Chemical Industries, Ltd. | Derives de chromone, leur procede de preparation et leur utilisation |
EP1268486A2 (en) * | 2000-03-31 | 2003-01-02 | Takeda Chemical Industries, Ltd. | Fused heterocyclic derivatives, their production and use |
US20030216358A1 (en) * | 2001-07-05 | 2003-11-20 | Muchmore Douglas Boyer | Method for enhancing bone mineral density gain |
KR20040087335A (ko) * | 2002-03-01 | 2004-10-13 | 야마노우치세이야쿠 가부시키가이샤 | 질소 함유 복소환 화합물 |
EP1556057A4 (en) * | 2002-08-29 | 2009-07-15 | Univ California | AGENTS AND METHODS FOR STIMULATING BONE FORMATION |
-
2004
- 2004-06-30 EP EP04747073A patent/EP1640010A1/en not_active Withdrawn
- 2004-06-30 WO PCT/JP2004/009604 patent/WO2005002590A1/ja active Application Filing
- 2004-06-30 JP JP2005511387A patent/JPWO2005002590A1/ja not_active Withdrawn
- 2004-06-30 US US10/563,107 patent/US20060173009A1/en not_active Abandoned
- 2004-06-30 CA CA002529558A patent/CA2529558A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001507338A (ja) * | 1996-11-25 | 2001-06-05 | メルク エンド カンパニー インコーポレーテッド | 疾患を治療するために同時投与されるアンドロゲン物質とビスホスホン酸物質 |
JP2002541095A (ja) * | 1999-04-06 | 2002-12-03 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | アリールアルカノイルピリダジンの使用 |
JP2001163862A (ja) * | 1999-09-27 | 2001-06-19 | Sankyo Co Ltd | テトラヒドロピリダジン誘導体 |
JP2004504351A (ja) * | 2000-07-19 | 2004-02-12 | イーライ・リリー・アンド・カンパニー | 骨量増加の増強方法 |
JP2004002318A (ja) * | 2002-03-01 | 2004-01-08 | Yamanouchi Pharmaceut Co Ltd | 含窒素複素環化合物 |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008543764A (ja) * | 2005-06-09 | 2008-12-04 | ブリストル−マイヤーズ スクイブ カンパニー | 11β−ヒドロキシステロイドデヒドロゲナーゼI型阻害剤としてのイミダゾおよびトリアゾロピリジン類 |
US8030305B2 (en) | 2005-12-21 | 2011-10-04 | Janssen Pharmaceutica N.V. | Triazolopyridazines as kinase modulators |
US8173654B2 (en) | 2005-12-21 | 2012-05-08 | Janssen Pharmaceutica N.V. | Triazolopyridazine compounds |
WO2009017222A1 (ja) * | 2007-08-02 | 2009-02-05 | Teijin Pharma Limited | 骨代謝異常に起因する疾患の予防剤又は治療剤 |
JPWO2009017222A1 (ja) * | 2007-08-02 | 2010-10-21 | 帝人ファーマ株式会社 | 骨代謝異常に起因する疾患の予防剤又は治療剤 |
JP2011529876A (ja) * | 2008-08-01 | 2011-12-15 | ドン ファ ファーマシューティカル カンパニー リミテッド | ベンズアミジン誘導体またはその塩、およびビスフォスフォネートを含む骨粗鬆症の予防または治療用薬学組成物 |
JP2011529875A (ja) * | 2008-08-01 | 2011-12-15 | ドン ファ ファーマシューティカル カンパニー リミテッド | ベンズアミジン誘導体またはその塩、およびアレンドロン酸またはその塩を含む骨粗鬆症の予防または治療用薬学的組成物 |
US8816082B2 (en) | 2010-05-28 | 2014-08-26 | The Royal Institution For The Advancement Of Learning/Mcgill University | Heterocyclyl-pyridinyl-based biphosphonic acid, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof |
US9290526B2 (en) | 2010-05-28 | 2016-03-22 | The Royal Institution For The Advancement Of Learning/Mcgill University | Heterocyclyl-pyridinyl-based biphosphonic acid, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof |
US8796261B2 (en) | 2010-12-02 | 2014-08-05 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
US9249161B2 (en) | 2010-12-02 | 2016-02-02 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
US9522920B2 (en) | 2010-12-02 | 2016-12-20 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
US9422292B2 (en) | 2011-05-04 | 2016-08-23 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
WO2012174487A3 (en) * | 2011-06-17 | 2013-04-25 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
US9328117B2 (en) | 2011-06-17 | 2016-05-03 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
US9493483B2 (en) | 2012-06-06 | 2016-11-15 | Constellation Pharmaceuticals, Inc. | Benzo [C] isoxazoloazepine bromodomain inhibitors and uses thereof |
US9624244B2 (en) | 2012-06-06 | 2017-04-18 | Constellation Pharmaceuticals, Inc. | Benzo [B] isoxazoloazepine bromodomain inhibitors and uses thereof |
US9925197B2 (en) | 2012-06-06 | 2018-03-27 | Constellation Pharmaceuticals, Inc. | Benzo [C] isoxazoloazepine bromodomain inhibitors and uses thereof |
US9969747B2 (en) | 2014-06-20 | 2018-05-15 | Constellation Pharmaceuticals, Inc. | Crystalline forms of 2-((4S)-6-(4-chlorophenyl)-1-methyl-4H-benzo[C]isoxazolo[4,5-e]azepin-4-yl)acetamide |
Also Published As
Publication number | Publication date |
---|---|
EP1640010A1 (en) | 2006-03-29 |
JPWO2005002590A1 (ja) | 2006-08-10 |
CA2529558A1 (en) | 2005-01-13 |
US20060173009A1 (en) | 2006-08-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005002590A1 (ja) | 骨量増加誘導剤 | |
US7173033B2 (en) | Nitrogen-containing heterocyclic compound | |
EP2813498B1 (en) | Compounds for Alzheimer's disease | |
CN108349964A (zh) | N-(吡啶-2-基)-4-(噻唑-5-基)嘧啶-2-胺类化合物作为治疗性化合物 | |
JP5689119B2 (ja) | ジヒドロピリミジン化合物及び合成方法、医薬組成物及びその使用 | |
KR20210006407A (ko) | Rip1 억제 화합물 및 이를 제조하고 사용하는 방법 | |
JP5595402B2 (ja) | アンドロゲン受容体モジュレーターとしての新規イミダゾリジン化合物 | |
CN104530052A (zh) | 用于激酶调节的5h-吡咯[2,3-b]吡嗪衍生物和其适应症 | |
AU2005205118A1 (en) | Phenyl-[4-(3-phenyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amine derivatives as IGF-IR inhibitors | |
JP2021193149A (ja) | 末梢セロトニンと関連する疾患または障害を処置するためのトリプトファンヒドロキシラーゼ1(tph1)の結晶性スピロ環式化合物インヒビター | |
TW201040169A (en) | Imidazole substituted pyrimidines 724 | |
EA020609B1 (ru) | ИМИДАЗО[1,2-а]ПИРИДИН-2-ИЛФЕНИЛ ПРОИЗВОДНЫЕ ДЛЯ ЛЕЧЕНИЯ РАКА | |
CN100409840C (zh) | GSK-3β抑制剂在制备增加骨生成的药物中的应用 | |
TW201309698A (zh) | 四氫咔啉衍生物 | |
EA029311B1 (ru) | Hантагонисты, имеющие феноксипиперидиновое ядро в структуре, и их применение для лечения и/или профилактики состояний, опосредуемых hрецепторами | |
JP2022538270A (ja) | 3-(5-メチル-1,3-チアゾール-2-イル)-n-{(1r)-1-[2-(トリフルオロメチル)ピリミジン-5-イル]エチル}ベンズアミドのアナログ | |
WO2021060453A1 (ja) | 架橋型光学活性2級アミン誘導体 | |
JP2012523376A (ja) | Brca2活性が低下した癌対象の治療のためのsns−595の使用方法 | |
TW201410246A (zh) | Amg 900治療癌症之用途 | |
JP5777011B2 (ja) | コルホルシンダロパートを含む骨疾患の予防または治療用組成物 | |
KR101856266B1 (ko) | 카세인 키나아제 1δ 및 카세인 키나아제 1ε 저해제 | |
WO2001058489A1 (fr) | Agents prophylactiques/therapeutiques contre le stress postoperatoire | |
US20090221576A1 (en) | Pharmaceutical Use of 2-Hydroxy-3-[5-(Morpholin-4-Ylmethyl) Pyridin-2-YL]-1H-IN-Dole-5-Carbonitrile as a Free Base or Salts | |
JP7091455B2 (ja) | ピリジノン誘導体及びそれらの選択的alk-2阻害剤としての使用 | |
CA3104235A1 (en) | 4-substituted phenyl-1,3,5-triazine derivatives as modulators of trk receptors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005511387 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2529558 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004747073 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2006173009 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10563107 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2004747073 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10563107 Country of ref document: US |